AstraZeneca Promotes Sipavibart to Prevent COVID-19 in Immunocompromised Patients
The EMA has given AstraZeneca the green light to market Sipavibart, a long-acting drug intended to prevent COVID-19 in immunocompromised people.
AstraZeneca’s marketing authorization application (MAA) for sipavibart has been accepted by the European Medicines Agency (EMA) under the accelerated evaluation procedure for pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. The molecule is an antibody acting… + more
Positive Covid-19 antibody tests in immunosuppressed patients
SUPERNOVA shows that sipavibart, AstraZeneca’s long-acting antibody, significantly reduces symptomatic disease in immunocompromised patients. The results highlight its effectiveness against different variants of the virus. + read more
Hospital Sant Pau participates in the IMMUNOcare program against Covid in immunocompromised patients.
The project, promoted by AstraZeneca, aims to improve the identification of such patients, analyze and standardize their approach, and optimize immunization consultations. + read more
IBiS reveals the effectiveness of simultaneous administration of Covid and influenza vaccines
The discovery addresses concerns about possible interactions between the vaccines, which has led to uncertainty about their effectiveness when used in combination. + read more
Carlos Navarro will head AstraZeneca’s vaccines and immunotherapy division in Spain.
With a degree in pharmacy and more than two decades of experience in the pharmaceutical industry, Navarro takes on the company’s strategic direction, which is focused on developing solutions to protect the most vulnerable patients from serious infections. + read more
Positive results from the ECHO phase III study
AstraZeneca presented results from the phase III ECHO trial showing significant improvement in PFS compared with standard chemotherapy. + read more
IMMUNOcare: optimizing care for immunocompromised patients
The initiative was launched by AstraZeneca to improve the identification of such patients, analyze and standardize their approach, and optimize immunization consultations using LEAN methodology. + read more